A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Inclusion Criteria:

Adults, age 18 years or older
Histologically confirmed unresectable or metastatic cutaneous melanoma
Documented radiological progression on prior treatment(s) that included an anti-PD-1/L1 agent
Available tumor tissue OR be willing to provide a fresh tumor biopsy
Presence of at least one measurable lesion as assessed by CT and/or MRI according to RECIST 1.1
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1
Adequate organ and bone marrow function

Exclusion Criteria:

Known hypersensitivity to monoclonal antibodies, any of the IPs, or excipients contained in these products
Current anti-cancer therapy, other investigational treatment, or any participation in other interventional trials
Prior exposure to any therapy that targets the same target as the product under investigation, except for PD-1/L1
Known symptomatic/active untreated central nervous system (CNS) metastasis
Inadequate recovery from toxicity and/or complications attributable to any previous anti-cancer therapy
Inadequate recovery from all recent surgeries
At least 1-week from the time of minor surgery and at least 4 weeks from a major surgery
Received a live vaccine within 30 days prior to randomization (or planned to receive a live attenuated vaccine during the study)
History of HIV infection (positive HIV test, not on antiretroviral therapy, detectable viral load)
Active hepatitis B (positive hepatitis B surface antigen test) or hepatitis C infection (positive hepatitis C antibody)
Documented history or current diagnosis of clinically significant cardiac disease
History of or present CNS disease unrelated to cancer, unless adequately treated with standard medical therapy
Received solid organ or bone marrow transplantation
History of non-infectious pneumonitis requiring corticosteroid therapy within 1 year prior to enrollment, or current presence of interstitial lung disease
Active or previously documented autoimmune disease including but not limited to inflammatory bowel disease, diverticulitis, celiac disease, systemic lupus erythematosus, Wegener syndrome, multiple sclerosis, and vasculitis
Requiring long term systemic corticosteroids, except topical cortical steroids for intranasal inhalation or physiological dose
Active gastrointestinal (GI) bleeding or GI perforation or fistula
Serious active infection requiring intravenous (IV) antibiotics and/or hospitalization at study entry
Pregnant or lactating women or women who intend to get pregnant or lactate during the study and up to 120 days after the end of treatment